These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32566150)

  • 21. Value-based pricing: incentive for innovation or zero net benefit?
    Hughes DA
    Pharmacoeconomics; 2011 Sep; 29(9):731-5. PubMed ID: 21736392
    [No Abstract]   [Full Text] [Related]  

  • 22. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why we should contain the "medical-industrial-media complex".
    Lotufo PA
    Sao Paulo Med J; 2004 Mar; 122(2):39-40. PubMed ID: 15257357
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research on green supply chain coordination strategy for uncertain market demand.
    Cao J; Chen Y; Lu B; Tong C; Zhou G
    Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):687-92. PubMed ID: 25796145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excluding NICE from early stages of value based pricing scheme was "big win for pharma," conference is told.
    Limb M
    BMJ; 2013 Nov; 347():f6906. PubMed ID: 24246840
    [No Abstract]   [Full Text] [Related]  

  • 27. [Essential drugs available to all].
    Bol Oficina Sanit Panam; 1992; 113(5-6):539-43. PubMed ID: 1296697
    [No Abstract]   [Full Text] [Related]  

  • 28. Business of Health. International Healthcare.
    Berry MD;
    Issue Brief Health Policy Track Serv; 2018 Dec; 2018():1-36. PubMed ID: 30681305
    [No Abstract]   [Full Text] [Related]  

  • 29. Was Part D a giveaway to the pharmaceutical industry?
    Newhouse JP; Seiguer E; Frank RG
    Inquiry; 2007; 44(1):15-25. PubMed ID: 17583259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions.
    Barbieri E; Huang M; Pi S; Tassinari M
    Int J Environ Res Public Health; 2017 Oct; 14(10):. PubMed ID: 28981463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shortcomings in the US Pharmaceutical Supply Chain: Potential Risks Associated With International Manufacturing and Trade-Related Tariffs.
    Oehler RL; Gompf SG
    JAMA; 2020 Jul; 324(2):143-144. PubMed ID: 32176256
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Provincially administered universal pharmacare programs require a secure, affordable drug supply: A matter of national security?
    McAlister VC
    Can J Surg; 2018 Aug; 61(4):220-221. PubMed ID: 30067177
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug policy in China: pharmaceutical distribution in rural areas.
    Dong H; Bogg L; Rehnberg C; Diwan V
    Soc Sci Med; 1999 Mar; 48(6):777-86. PubMed ID: 10190640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug shortage: determinants, consequences and management].
    Reis AM; Perini E
    Cien Saude Colet; 2008 Apr; 13 Suppl():603-10. PubMed ID: 21936164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An insight into the pharmaceutical sector in Yemen during conflict: challenges and recommendations.
    Alshakka M; Mohamed Ibrahim MI; Bahattab A; Badulla WFS; Shankar PR
    Med Confl Surviv; 2020 Sep; 36(3):232-248. PubMed ID: 32718201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.